DexCom, Inc. (NASDAQ:DXCM) SVP Heather S. Ace sold 4,258 shares of the company’s stock in a transaction that occurred on Friday, November 9th. The stock was sold at an average price of $147.32, for a total value of $627,288.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Heather S. Ace also recently made the following trade(s):

  • On Monday, September 10th, Heather S. Ace sold 1,832 shares of DexCom stock. The stock was sold at an average price of $143.76, for a total value of $263,368.32.

Shares of DXCM opened at $142.73 on Wednesday. DexCom, Inc. has a 52-week low of $50.55 and a 52-week high of $152.14. The company has a quick ratio of 4.43, a current ratio of 4.71 and a debt-to-equity ratio of 0.60.

DexCom (NASDAQ:DXCM) last announced its earnings results on Tuesday, November 6th. The medical device company reported $0.17 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.12) by $0.29. DexCom had a negative return on equity of 2.89% and a net margin of 4.72%. The company had revenue of $266.70 million for the quarter, compared to analyst estimates of $242.72 million. DexCom’s revenue was up 44.5% on a year-over-year basis. Analysts anticipate that DexCom, Inc. will post -0.19 earnings per share for the current fiscal year.

DXCM has been the subject of a number of analyst reports. Northland Securities upgraded DexCom from an “under perform” rating to a “market perform” rating in a report on Wednesday, September 12th. Stephens upped their target price on DexCom from $135.00 to $160.00 and gave the company an “overweight” rating in a research report on Thursday, August 23rd. Canaccord Genuity upped their target price on DexCom from $125.00 to $150.00 and gave the company a “buy” rating in a research report on Thursday, August 23rd. Goldman Sachs Group raised DexCom from a “sell” rating to a “neutral” rating and set a $125.00 target price on the stock in a research report on Friday, October 19th. Finally, Piper Jaffray Companies upped their target price on DexCom to $150.00 and gave the company an “overweight” rating in a research report on Thursday, August 2nd. Seven research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. DexCom presently has an average rating of “Buy” and an average target price of $132.50.

Several hedge funds have recently bought and sold shares of the stock. State Board of Administration of Florida Retirement System raised its position in shares of DexCom by 0.4% during the 2nd quarter. State Board of Administration of Florida Retirement System now owns 120,747 shares of the medical device company’s stock valued at $11,469,000 after acquiring an additional 470 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of DexCom by 9.3% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,552 shares of the medical device company’s stock valued at $527,000 after acquiring an additional 471 shares in the last quarter. Metropolitan Life Insurance Co. NY raised its position in shares of DexCom by 7.6% during the 2nd quarter. Metropolitan Life Insurance Co. NY now owns 6,879 shares of the medical device company’s stock valued at $653,000 after acquiring an additional 486 shares in the last quarter. Xact Kapitalforvaltning AB raised its position in shares of DexCom by 4.1% during the 2nd quarter. Xact Kapitalforvaltning AB now owns 12,700 shares of the medical device company’s stock valued at $1,206,000 after acquiring an additional 500 shares in the last quarter. Finally, Advisory Research Inc. raised its position in shares of DexCom by 17.2% during the 3rd quarter. Advisory Research Inc. now owns 4,084 shares of the medical device company’s stock valued at $584,000 after acquiring an additional 598 shares in the last quarter.

TRADEMARK VIOLATION NOTICE: “DexCom, Inc. (DXCM) SVP Heather S. Ace Sells 4,258 Shares” was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this article on another publication, it was illegally stolen and republished in violation of US & international trademark & copyright law. The legal version of this article can be read at https://www.thecerbatgem.com/2018/11/14/dexcom-inc-dxcm-svp-heather-s-ace-sells-4258-shares.html.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G5 mobile continuous glucose monitoring system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.

Further Reading: Tariff

Insider Buying and Selling by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.